Helsinn Discontinues Tumor Trial Program
Posted on: Friday, 17 November 2006, 09:00 CST
Exelixis has said that its licensee Helsinn Healthcare has discontinued enrollment of new patients in the becatecarin phase III clinical trial program in biliary tract tumors when it was found that chemotherapy was more effective.
Helsinn reported that despite some evidence of becatecarin activity, preliminary analysis of the phase III data by an independent data monitoring committee indicated that the comparator agent 5-fluorouracil demonstrated a greater than expected survival benefit, making it statistically improbable that the final study results could achieve the planned objectives for the trial.
Exelixis in-licensed becatecarin from Bristol-Myers Squibb in 2001 and subsequently out-licensed it to Helsinn in June 2005.
Becatecarin is a small molecule, anticancer compound for the treatment of hepatobiliary duct tumors, a rare and aggressive form of cancer with a high medical need and very limited survival. Becatecarin was granted orphan drug designation in the US and the European Union.
Source: Datamonitor
Related Articles
- Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc.
- Eisai and Helsinn Healthcare Announce FDA Approval for Aloxi Capsules
- Helsinn Introduces Aloxi Injection 0.075mg in US
- Helsinn Will Present at the 26th Annual J.P. Morgan Healthcare Conference, San Francisco
- MGI Pharma and Helsinn Say Aloxi Met Pivotal Study Endpoint
- MGI PHARMA and HELSINN HEALTHCARE SA Announce Patent Extension for Aloxi(R) Injection
- Helsinn to Discontinue Becatecarin Trial Program
- Biovitrum to Distribute Helsinn's Antiemetic in Nordic Territories
- Helsinn and Biovitrum Enter a License Agreement for Nordic Marketing of Aloxi(R), a Drug That Prevents Nausea and Vomiting in Cancer Patients
 |
 |
User Comments (0)
RSS Feeds